Stem cell therapy: Promising treatment in heart failure?

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 73-80

  Loughran, John H ^a   Chugh, Atul R ^a   Ismail, Imtiaz ^b   Bolli, Roberto ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Bone marrow mononuclear stem cells; CAD; Chronic ischemic heart disease; Myogenesis; Stem cell therapy

Indexed keywords

5' NUCLEOTIDASE; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79 ANTIGEN; ENDOGLIN; HLA DR ANTIGEN; STEM CELL FACTOR; THY 1 ANTIGEN;

ACUTE HEART INFARCTION; ADIPOCYTE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARTILAGE CELL; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL PROGENITOR CELL; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; INTRACORONARY INFUSION; ISCHEMIC CARDIOMYOPATHY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MYOBLAST; OSTEOBLAST; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; STRESS ECHOCARDIOGRAPHY; SYSTEMATIC REVIEW;

EID: 84873705765     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0128-2     Document Type: Article

References (65)

1. • Roger VL, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220. Updated statistics regarding heart failure in the US, outlining the growing burden of this disease process in the US.
2. Avery CL, et al. The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2012;60(17):1640-6.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161-72.
4. McMurray JJV, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877-89.
5. Titler MG, et al. Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs. Health Serv Res. 2008;43(2):635-55.
6. •• Menasche P, et al. Autologous skeletal myoblast transplantation for cardiac insufficiency. First clinical case. Arch Mal Coeur Vaiss. 2001;94(3):180-2. First ever report of stem cell therapy for cardiac repair.
7. Menasche P, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41(7):1078-83.
8. Menasche P, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189-200.
9. Duckers HJ, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011;6(7):805-12.
10. •• Strauer BE, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106(15):1913-8. First ever clinical trial of stem cell therapy for cardiac repair.
11. Assmus B, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-17.
12. Wollert KC, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141-8.
13. Schachinger V, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1210-21.
14. Lunde K, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199-209.
15. Meyer GP, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113(10):1287-94.
16. Traverse JH, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380-9.
17. Surder D, et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI). Am Heart J. 2010;160(1):58-64.
18. Traverse JH, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110-9.
19. • Abdel-Latif A, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167(10):989-97. First meta-analysis to describe overall benefit of BMC in the setting of acute MI.
20. Strauer BE, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol. 2005;46(9):1651-8.
21. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12(7):721-9.
22. Assmus B, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355(12):1222-32.
23. Perin EC, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717-26.
24. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
25. Heng TS, et al. Stem cells-meet immunity. J Mol Med (Berl). 2009;87(11):1061-9.
26. El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev. 2004;13(5):463-72.
27. Chen SL, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94(1):92-5.
28. Florenzano F, Minguell JJ. Autologous mesenchymal stem cell transplantation after acute myocardial infarction. Am J Cardiol. 2005;95(3):435.
29. Katritsis DG, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv. 2005;65(3):321-9.
30. Chen S, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18(11):552-6.
31. Lo R, Hsia HH. Ventricular arrhythmias in heart failure patients. Cardiol Clin. 2008;26(3):381-403. vi.
32. Katritsis DG, et al. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace. 2007;9(3):167-71.
33. Hare JM, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-79.
34. Trachtenberg B, et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011;161(3):487-93.
35. Bartunek J, et al. C-Cure multicenter triall: lineage specified bone marrow derived cardiopoietic mesenchymal stem cells for treatment of ischemic cardiomyopathy. J Am Coll Cardiol. 2011;57:E200.
36. Beltrami AP, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344(23):1750-7.
37. Quaini F, et al. Chimerism of the transplanted heart. N Engl J Med. 2002;346(1):5-15.
38. Bergmann O, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102.
39. •• Beltrami AP, Beltrami AP, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-76. First report of the discovery of endogenous stem cells recovered from the mammalian heart.
40. Messina E, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911-21.
41. •• Bolli R, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847-57. First in-human clinical trial of CSC for the treatment of post-infarction left ventricular dysfunction.
42. Chugh AR, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11 Suppl 1):S54-64.
43. •• Makkar RR, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904. First clinical trial investigating the use of CDC for the treatment of ischemic heart disease.
44. Cheng K, et al. Magnetic enhancement of cell retention, engraftment and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant. 2012;21(6):1121-35.
45. Terrovitis J, et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol. 2009;54(17):1619-26.
46. Freyman T, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006;27(9):1114-22.
47. Frangogiannis NG. The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. J Am Coll Cardiol. 2011;58(23):2424-6.
48. Martin-Rendon E, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29(15):1807-18.
49. Kutschka I, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation. 2006;114(1 Suppl):I167-73.
50. Memon IA, et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg. 2005;130(5):1333-41.
51. Christman KL, et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44(3):654-60.
52. Suzuki K, et al. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation. 2000;102(19 Suppl 3):III216-21.
53. Laflamme MA, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005;167(3):663-71.
54. Niagara MI, et al. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007;100(4):545-55.
55. Pasha Z, et al. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008;77(1):134-42.
56. Pons J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun. 2008;376(2):419-22.
57. Barbash IM, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863-8.
58. Gupta R, Losordo DW. Challenges in the translation of cardiovascular cell therapy. J Nucl Med. 2010;51 Suppl 1:122S-7.
59. Flett AS, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150-6.
60. Hung J, et al. Cardiac image modeling tool for quantitative analysis of global and regional cardiac wall motion. Invest Radiol. 2009;44(5):271-8.
61. Hulten EA, et al. Stress CT perfusion: coupling coronary anatomy with physiology. J Nucl Cardiol. 2012;19(3):588-600.
62. Morton G, et al. Quantitative cardiovascular magnetic resonance perfusion imaging: inter-study reproducibility. Eur Heart J Cardiovasc Imaging. 2012;13(11):954-60.
63. Haas F, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30(7):1693-700.
64. Baer FM, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation. 1995;91(4):1006-15.
65. Tillisch J, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884-8.